Phaseline

Targets › 3CLPRO

3CLPRO: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Jun 2028.

Open in Phaseline: the race on 3CLPRO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Icahn School of Medicine at Mount SinaiPaxlovid
Combination of nirmatrelvir (SARS-CoV-2 protease inhibitor) and ritonavir (CYP3A4 inhibito
3CLPROPhase 2Post-acute Sequelae of COVID-19Jun 2028

Conditions

Post-acute Sequelae of COVID-19 (1)

Modalities

small molecule (1)

Companies

Icahn School of Medicine at Mount Sinai (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.